Trial Profile
Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2020
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Roche
- 18 Dec 2019 Status changed from active, no longer recruiting to completed.
- 09 Jul 2019 Planned End Date changed from 24 Jun 2020 to 14 Feb 2020.
- 09 Jul 2019 Planned primary completion date changed from 24 Jun 2020 to 14 Feb 2020.